LONDON – Complix NV is in the thick of a €15 million to €20 million (US$19 million to $25 million) Series B fundraising, as it prepares to move the first of its intracellular-targeting Alphabodies into Phase I trials in 2013. Read More
LONDON – A new low-cost technique will allow scientists to easily monitor all the genes and proteins being switched on and off in different cells under different circumstances. Read More
Without much fanfare, Bone Therapeutics SA has begun a pivotal double-blinded Phase III trial of a cell therapy for osteonecrosis, a debilitating bone disorder affecting young adults. Read More
LONDON – Following the award of the Nobel Prize for Medicine to Shinya Yamanaka for his discovery of how to reprogram adult skin cells back to pluripotent stem cells, large-scale initiatives to use the technique for the creation of specialized cell banks are taking shape in Europe. Read More
Vaccibody AS received €2 million (US$2.5 million) to have a crack at a problem that has eluded firms with far greater resources: developing an effective therapeutic vaccine against human papillomavirus (HPV) infection. Read More
Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said last week the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief. Read More
• CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7.1 showed promising safety and tolerability in heavily pretreated solid tumors. The compound also demonstrated signs of efficacy in most treated patients, suggesting longer overall survival in lung, hypopharnyx, ovarian, testicular, stomach, esophageal, biliary tract and neuroendocrine tumors. Read More
